Is the price fair?
What BMY's price assumes
Bristol Myers Squibb trades at 14.9× earnings against 27.4× for the median Drug Manufacturers - General name, cheaper than its own group.
14.9
Trailing P/E · Drug Manufacturers - General median 27.4 · cheaper than the typical name in its group
- Price / sales
- 2.53
Price / sales · as of 2026-Q1
- Free cash flow yield
- 10%
Free cash flow yield · Drug Manufacturers - General median 5.8%
- Growth the price implies
- −4.1%
Growth the price implies · The price pays for −4.1% free cash flow growth a year for a decade; the business has delivered +2.2% a year over the last three.
Details›
- Price / book2026-Q1
- 6.12
- EV / sales2026-Q1
- 3.25
- Healthcare median P/E362 names
- 31.5
- Drug Manufacturers - General median P/E16 names
- 27.4
- Free cash flow, trailing twelve months
- $11.4B
- Market capitalisation
- $110.3B
- 3-year revenue growth
- +2.9%
- 3-year free cash flow growth
- +2.2%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $72.20 |
| Its own P/E history, median | $90.28 |
| Its own P/E history, upper quartile | $132.44 |
| 52-week range | $41.67 – $67.93 |
| Today | $67.58 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - General
Ranks #7 of 16 by Smart Score